Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma - guidance (TA649)

NICE recommends use of polatuzumab vedotin with rituximab and bendamustine as an option for treating relapsed or refractory diffuse large B cell lymphoma in adults who cannot have a haematopoietic stem cell transplant, if company provides it according to commercial arrangement.

National Institute for Health and Care Excellence